Overview

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Status:
Completed
Trial end date:
2021-03-15
Target enrollment:
Participant gender:
Summary
The objectives of this study are: - To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine - To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) - To evaluate the safety of Nyxol - To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis
Phase:
Phase 3
Details
Lead Sponsor:
Ocuphire Pharma, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Phentolamine